Health Utility Adjusted Survival: a Composite

Endpoint for Clinical Trial Designs

- 3 Yangqing Deng¹, PhD, John R. de Almeida^{2,3}, MD, MSc, FRCSC, Wei Xu^{1,4*}, PhD
- ⁴ ¹Department of Biostatistics, University Health Network, Toronto, ON, Canada
- ⁵ ²Department of Otolaryngology—H&N Surgery, University Health Network, Toronto, ON, Canada
- ³Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
- ⁴Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
- 8 ^{*}Corresponding author: Wei Xu, Email: <u>wei.xu@uhnresearch.ca</u>
- 9 Address: 10-511, 610 University Ave, Toronto, M5G 2M9
- 10 Tel: (416)946-4501

2

11 ABSTRACT

Many randomized trials have used overall survival as the primary endpoint for establishing non-12 13 inferiority of one treatment compared to another. However, if a treatment is non-inferior to 14 another treatment in terms of overall survival, clinicians may be interested in further exploring which treatment results in better health utility scores for patients. Examining health utility in a 15 16 secondary analysis is feasible, however, since health utility is not the primary endpoint, it is 17 usually not considered in the sample size calculation, hence the power to detect a difference of health utility is not guaranteed. Furthermore, often the premise of non-inferiority trials is to test 18 19 the assumption that an intervention provides superior quality of life or toxicity profile without compromising the survival when compared to the existing standard. Based on this consideration, 20 it may be beneficial to consider both survival and utility when designing a trial. There have been 21 22 methods that can combine survival and quality of life into a single measure, but they either have

1	strong restrictions or lack theoretical frameworks. In this manuscript, we propose a method
2	called HUS (Health Utility adjusted Survival), which can combine survival outcome and
3	longitudinal utility measures for treatment comparison. We propose an innovative statistical
4	framework as well as procedures to conduct power analysis and sample size calculation. By
5	comprehensive simulation studies involving summary statistics from the PET-NECK trial, ¹ we
6	demonstrate that our new approach can achieve superior power performance using relatively
7	small sample sizes, and our composite endpoint can be considered as an alternative to overall
8	survival in future clinical trial design and analysis where both survival and health utility are of
9	interest.
10	

Keywords: Health utility; Overall survival; Time-to-event data; Hazard ratio; Proportional
hazards; Randomized controlled trials

1 1. INTRODUCTION

2 In many clinical studies, overall survival (OS) is used as the primary endpoint to assess efficacy 3 of treatments. Superiority trials are used to test whether a new treatment is better than a standard 4 or control treatment, while non-inferiority trials are used to test whether the new treatment is not unacceptably worse than control. Non-inferiority trials are especially important in circumstances 5 6 where the new treatment may have other benefits (e.g., lower costs, fewer side effects, improved 7 quality of life, or is easier to implement) compared to control, and people are only interested in 8 showing the new treatment is not worse than control in terms of OS. When non-inferiority has 9 been established, clinicians may be interested in further examining whether the new treatment can benefit patients more in terms of health utility.¹ Health utility is a construct, usually ranging 10 from 0 to 1 (although theoretically can also have negative values), that quantifies the preference 11 12 for a given health state experienced by a patient at a certain time point. A higher value means a healthier state, while death usually corresponds to 0. Using health utility scores at different time 13 14 point during the treatment and post-treatment, statistical analysis may be performed to compare different treatment groups' utility scores.^{2–4} However, given that the study design is usually 15 based on the primary endpoint of OS without considering health utility, whether there will be 16 17 enough power for health utility analysis is uncertain. Also, conducting tests for OS and health 18 utility separately may not be the most efficient, because it involves multiple testing adjustment 19 and can lose statistical power. Hence, it may be beneficial to consider using a composite 20 endpoint that combines survival and utility, which may lead to increased statistical power and 21 smaller required sample sizes.

22

1 Creation of a composite endpoint of survival and utility, can also aid in clinical interpretation of 2 non-inferiority trials where non-inferiority of survival is not the only acceptable outcome. For example, a new therapeutic intervention may be purported as offering improvements in quality of 3 4 life or toxicity. However, clinicians may not be willing to sacrifice disease control to provide these other benefits. In this case, testing this new intervention in phase 3 non-inferiority trial 5 6 where overall survival is the primary outcome and quality of life or toxicity is a secondary 7 outcome may establish the intervention as non-inferior from a survival perspective and then falsely identify the new intervention as a standard of care without appropriate consideration of 8 9 quality of life and toxicity. On the other hand, one may consider a situation where a patients' 10 preference for improved quality of life (or utility) may outweigh their desire to have non-inferior survival. In this instance, demonstration of superiority of utility may not be enough if it is 11 12 associated with a significant loss of survival and the two outcomes cannot be interpreted in isolation. In this instance, a combination of both survival and utility endpoints may be needed to 13 14 declare a new intervention superior.

15

Some methods that can combine survival and utility have been proposed and used to analyze 16 clinical trial data, and the most commonly used method is called Q-TWiST (Quality-adjusted 17 Time Without Symptoms of disease or Toxicity).^{5–12} Though Q-TWiST has not been commonly 18 19 seen as a primary endpoint for designing new studies, researchers have derived its statistical properties as well as formulas for sample size calculations.⁸ That being said, one major issue 20 about Q-TWiST is that it divides each patient's status into three states (toxicity, time without 21 symptoms and toxicity, and relapse) and uses pre-selected weights for different states. In many 22 23 scenarios, with utility scores measured as continuous variables at different time points

throughout the trials, it may be much more desirable to analyze them in their original scales
 rather than forcing to have three categories, which may likely result in loss of information and
 decreased statistical power.

4

5 QALY (Quality-Adjusted Life Years), of which Q-TWiST can be considered as a special case, is the most intuitive way to combine survival with utility when comparing different treatments.^{5, 13–} 6 ¹⁷ It has also been used in the field of cost utility analysis, where similar methods have been 7 proposed and compared.^{18–21} Quality-adjusted progression-free survival, a similar concept with 8 9 slightly different focus, has also been used to assess the benefits of different treatments in randomized trials.²²⁻²⁴ However, such measures have rarely been considered as a primary 10 endpoint for designing new trials, and we are not aware of any detailly developed statistical 11 12 framework or comprehensive simulation studies that demonstrate the advantages and feasibility of a quality-adjusted survival endpoint compared to the traditional survival endpoint. 13 14

With these limitations and considerations, we propose an innovative composite endpoint for combining longitudinal health utility and survival, called HUS (Health Utility adjusted Survival), with a detailed statistical testing framework as well as procedures to perform power analysis and sample size calculations. By assigning weights to health utility and survival, HUS can be modified to suit different scenarios with increased power.

20

This new endpoint may help better interpret the findings in clinical trials. Often non-inferiority trials are plagued with uncertainty of the efficacy of a new intervention that is statistically deemed non-inferior based mainly on survival estimates but that has not been clearly shown to

1 be more effective from a toxicity reduction or quality of life improvement perspective. In Table 1, 2 we provide several scenarios of how the new composite endpoint of HUS may improve 3 interpretation of clinical trial findings if this composite endpoint was used in place of standard 4 primary endpoints. For example, one may consider three scenarios in which a new treatment is 5 deemed non-inferior based on a primary outcome of survival in a typical non-inferiority design where different utility scores may produce drastically different trial conclusions if a composite 6 7 HUS endpoint were used. If a new intervention had lower utility than the comparator, a non-8 inferior trial would declare the new intervention non-inferior, when in fact, a HUS endpoint 9 would appropriately declare the new intervention inferior. In addition, as we will show in the 10 simulations, sufficient power may be achieved with smaller sample sizes to make statistical inferences than non-inferiority trials based on a non-inferiority margin of survival. This feature 11 12 may improve the efficiency of trial conduct and arriving at meaningful conclusions with smaller 13 samples.

14

This manuscript is structured as follows. In section 2, we present the methodology of the HUS endpoint, including its construction, sample size calculation and power analysis. In section 3, we use comprehensive simulation studies with various settings, including scenarios incorporating parameter estimates based on the PET-NECK trial¹ to demonstrate the power advantage of HUS when analyzing study data and its potential to reduce required sample sizes when designing new trials. At last, we provide a discussion on the advantages, limitations and future directions for HUS in section 4.

22

1 2. METHODS

2 2.1. HEALTH UTILITY ADJUSTED SURVIVAL (HUS)

3 In this section, we describe the basic framework of Health Utility adjusted Survival (HUS). In

4 many clinical studies, overall survival is chosen as the primary endpoint, which determines the

5 sample size, while health utility scores are usually analyzed in the secondary analyses. To

6 construct a composite endpoint combining survival and health utility, we can take the product of

7 the survival curve and the utility curve, as illustrated by Figure 1.

8

9 Suppose the total length of the study follow up time is *T*, and we are interested in comparing

10 survival and health utility between treatment groups 1 and 2. We define a Q statistic to represent

11 the HUS of each treatment group as

$$Q_{1} = \int_{0}^{T} S_{1}(t) \overline{U}_{1}(t) dt,$$

$$Q_{2} = \int_{0}^{T} S_{2}(t) \overline{U}_{2}(t) dt,$$
(1)
(2)

where $S_1(t)$ and $\overline{U}_1(t)$ are the survival function (proportion of patients alive at t) and average utility score of those alive at t for group 1. $S_2(t)$ and $\overline{U}_2(t)$ are the survival function and average utility score of those alive at t for group 2. We propose to use the Kaplan Meier (KM) estimated survival functions $\hat{S}_1(t)$, $\hat{S}_2(t)$ to substitute $S_1(t)$, $S_2(t)$.

16

17 We can also assign weights to the survival and utility separately by defining

$$Q_{1} = \int_{0}^{T} [S_{1}(t)]^{\lambda_{1}} [\overline{U}_{1}(t)]^{\lambda_{2}} dt,$$

$$Q_{2} = \int_{0}^{T} [S_{2}(t)]^{\lambda_{1}} [\overline{U}_{2}(t)]^{\lambda_{2}} dt.$$
(4)

If $\lambda_1 = 0$ and $\lambda_2 = 1$, then Q_1 and Q_2 only consider the utility functions without including 1 survival. If $\lambda_1 = 1$ and $\lambda_2 = 0$, then Q_1 and Q_2 simply calculate the areas under the survival 2 curves without adjusting for utility. For simplicity, we suggest fixing the weight λ_1 as 1, since 3 survival is usually considered as important. λ_2 can be chosen from different values (e.g., 0.5, 1, 4 2), and $\lambda_2 = 1$ leads to the standard definition of HUS. The higher λ_2 is, the more importance is 5 assigned to health utility. For the rest of this manuscript, we focus on $\lambda_1 = 1$ and $\lambda_2 = 1$ unless 6 otherwise specified. We will also show some results with various λ_2 in our simulation studies 7 8 and discuss its effect.

9

10 2.2. Hypothesis Testing

To examine the difference of HUS between two treatment groups, we can define the test statisticas

$$\mathcal{T} = Q_1 - Q_2. \tag{5}$$

To perform a one-sided test on whether group 1 has better HUS than group 2, we can either use the bootstrap method to obtain the confidence interval of \mathcal{T} , or use the permutation method to obtain the distribution of \mathcal{T} under the null hypothesis.²⁵ We can reject or accept the null hypothesis (H0: $\mathcal{T} \leq 0$) based on bootstrap confidence intervals. Suppose groups 1 and 2 have n_1

1 and n_2 subjects respectively, and the chosen significance threshold is α . The bootstrap procedure 2 can be described as follows:

For iteration b (b = 1, ..., B), take a bootstrap dataset from the original samples, meaning
 that we randomly sample n₁ subjects with replacement from treatment group 1 to be group 1
 in the new sample, n₂ subjects with replacement from treatment group 2 to be group 2 in the
 new sample.

7 2. Calculate the \mathcal{T} test statistic for the new sample, denoted by $\mathcal{T}^{(b)}$.

8 3. After obtaining *T*^(b)'s (b = 1, ..., B), calculate the (1 – α) confidence interval based on
9 these *B* bootstrap samples. If the confidence interval does not contain 0, reject the null
10 hypothesis. Note that the confidence interval should be constructed based on the test of
11 interest (one-sided or two-sided).

12 The permutation procedure can be described as follows:

For iteration b (b = 1, ..., B), permute on the original samples to get a new permutation
 dataset, meaning that we randomly reassign all of the subjects into two groups with sample
 sizes n₁ and n₂.

16 2. Calculate the \mathcal{T} test statistic for the new sample, denoted by $\mathcal{T}^{(b)}$.

17 3. After obtaining $\mathcal{T}^{(b)}$'s (b = 1, ..., B), calculate the $(1 - \alpha)$ confidence interval based on

18 these *B* permutation samples. If the observed test statistic \mathcal{T} is outside the confidence interval, 19 reject the null hypothesis.

Note that the distribution generated by bootstrap is under the alternative hypothesis, whereas the distribution generated by permutation is under the null hypothesis, which is why the former is compared with 0, while the latter is compared with the observed test statistic. Based on our

1 experience, both bootstrap and permutation methods can control type I errors, but bootstrap tends 2 to have slightly higher power than permutation. Hence, we focus on the bootstrap method by 3 default. Some simulation results comparing bootstrap and permutation can be found in the supplementary materials (Table S4, Figure S1). Besides, as hinted by Glasziou et al.,¹³ Jackknife 4 resampling can also be used to obtain the distribution of \mathcal{T} under the alternative hypothesis.^{26, 27} 5 6 However, our past experience shows that there is little difference in terms of type I error and 7 power when comparing the bootstrap method with Jackknife, while the distribution of \mathcal{T} based 8 on bootstrap samples tends to be closer to normal. As a result, we suggest using the bootstrap 9 method as default. In terms of the number of resamples, B = 500 is usually sufficient for controlling type I errors and obtaining decent power. Examples showing the performance of 10 11 Jackknife and evaluating the choice of *B* are also provided in the supplementary materials 12 (Tables S4-S5, Figure S1).

13

14 2.3. THEORETICAL PROPERTIES

15 If we assume the survival time follows a piecewise exponential distribution, we can derive a 16 Monte Carlo approach to calculate the variance of the test statistic, which can be used for power 17 analysis and sample size calculation.²⁸ A similar idea was used by Royston and Parmar²⁹ to 18 calculate the variance for restricted mean survival time (RMST).^{30–32}

19

20 We consider a simple case with three key time points: 0 (baseline), C (end of surgery) and T (end

of study). Focusing on one treatment group, suppose the survival time is piecewise exponential,

22 with piecewise constant hazards h_1 , h_2 for time periods $0 \sim C$, $C \sim T$ respectively. The utility

23 function is piecewise linear, which starts from A_1 at time 0, changes to A_2 at time C, and then

- 1 goes to A_3 at time T. Let $X = \min(\xi, T)$, where ξ is the survival time with cumulative hazard
- 2 function H(t) and survival function S(t). We can decompose X as $X_1 + X_2$, where

$$X_1 = \begin{cases} \xi & (0 \le \xi \le C) \\ C & (\xi > C) \end{cases}, \tag{6}$$

$$X_{2} = \begin{cases} 0 & (0 \le \xi \le C) \\ \xi - C & (C < \xi \le T) \\ T - C & (\xi > T) \end{cases}$$
(7)

- 3 Denote $M = \int_{t=0}^{T} S(t)U_0(t)dt$ where $U_0(t)$ is the base utility function for the currently
- 4 considered treatment group. Write its statistic of HUS as $Q = \int_{t=0}^{T} \hat{S}(t) \overline{U}(t) dt$. If we define

$$X^* = A_1 X_1 + \frac{TA_2 - CA_3}{T - C} X_2 + \frac{A_2 - A_1}{2C} X_1^2 + \frac{A_3 - A_2}{2(T - C)} X_2^2 + \frac{A_3 - A_2}{T - C} X_1 X_2,$$
(8)

5 we can derive that $M = E(X^*)$. Following Royston & Parmar (2013), we can assume that for a 6 specific scenario, we have

$$SE(Q) = \phi \frac{SD(X^*)}{\sqrt{n}},$$
(9)

where ϕ is a factor no less than 1 and *n* is the sample size for the group we are currently looking at. For convenience, we call ϕ the variance balance factor, which takes account of the extra variance introduced into HUS by missing utility, censored survival, KM estimation, etc. SD(*X**) can be calculated using the parameters, while ϕ can be estimated by Monte Carlo sampling. More details including the derivations are provided in the supplementary materials (Tables S2-S3). We will demonstrate in our simulations that ϕ is robust to different sample sizes.

Note that when two treatment groups are compared, they should have their own variance balance
 factors, which we denote as \$\phi_1\$ and \$\phi_2\$. Applying our assumed property to each of the groups,
 we have

$$SE(Q_1) = \phi_1 \frac{SD(X_1^*)}{\sqrt{n_1}},$$
 (10)

$$SE(Q_2) = \phi_2 \frac{SD(X_2^*)}{\sqrt{n_2}},$$
 (11)

4 where Q_1 and Q_2 are the statistics of HUS for treatment groups 1 and 2, and n_1 , n_2 are the

sample sizes of the two groups. X_{1}^{*} and X_{2}^{*} are constructed separately for the two groups using

6 their own parameter settings. Hence, the variance of $\mathcal{T} = Q_1 - Q_2$ is

$$var(\mathcal{T}) = [SE(Q_1)]^2 + [SE(Q_2)]^2.$$
(12)

7 For the one-sided test, we can reject the null hypothesis if $T - z_{1-\alpha}\sqrt{\operatorname{var}(T)} > 0$.

8

9 2.4. POWER ANALYSIS AND SAMPLE SIZE CALCULATION

In any scenario with prespecified parameters, given different sample size, we can calculate the corresponding power of HUS using simulations. Then we can obtain a table showing different power under different sample sizes, which can be used to determine the sample size needed to achieve specific power (e.g., 80%) for a new trial. Detailed examples are provided in section 3.1.

15 If we assume that the special case described in section 2.3 is true, then we only need to run one

16 simulation given a fixed sample size (e.g., 200 subjects per treatment group), which can give us

1 estimates of ϕ_1 and ϕ_2 . For the one-sided test where we reject the null hypothesis if \mathcal{T} –

2 $z_{1-\alpha}\sqrt{\operatorname{var}(\mathcal{T})} > 0$, the power is

$$\omega = P\left(\mathcal{T} - z_{1-\alpha}\sqrt{\operatorname{var}(\mathcal{T})} > 0\right) = P\left(\mathcal{T} > z_{1-\alpha}\sqrt{\operatorname{var}(\mathcal{T})}\right).$$
(13)

3 Assume \mathcal{T} follows $N(\mathcal{T}_{true}, var(\mathcal{T}))$ and denote the power by ω , we have

$$\omega = \Phi\left(\frac{\mathcal{T}_{\text{true}}}{\sqrt{\operatorname{var}(\mathcal{T})}} - z_{1-\alpha}\right),\tag{14}$$

- 4 where Φ is the cumulative distribution function of the standard normal distribution. On the other
- 5 hand, to achieve power ω , the required sample sizes should satisfy

$$\phi_1^2 \frac{\mathrm{SD}(X_1^*)^2}{n_1} + \phi_2^2 \frac{\mathrm{SD}(X_2^*)^2}{n_2} = \left(\frac{\mathcal{T}_{\mathrm{true}}}{\Phi^{-1}(\omega) + z_{1-\alpha}}\right)^2.$$
(15)

6 If we assume $n_1 = n_2$, then the required sample size per arm is

$$n_1 = \frac{(\Phi^{-1}(\omega) + z_{1-\alpha})^2 [\phi_1^2 \operatorname{var}(X_1^*) + \phi_2^2 \operatorname{var}(X_2^*)]}{\mathcal{T}_{\text{true}}^2}.$$
 (16)

Note that it is difficult to calculate \mathcal{T}_{true} based on the setting of parameters. However, we can estimate it by using the average of the observed \mathcal{T} from our simulated samples. To summarize, in the special situation with simplified settings described in section 2.3, we can use the following procedure to calculate power yielded by a specific sample size:

- 11 1. Calculate $var(X_1^*)$, $var(X_2^*)$ based on parameter settings.
- 12 2. Simulate samples to estimate ϕ_1 , ϕ_2 and \mathcal{T}_{true} .
- 13 3. For each new sample size combination n_1 , n_2 , calculate SE(Q_1), SE(Q_2) using the estimated

14
$$\phi_1, \phi_2$$

1 4. Calculate $var(\mathcal{T})$ and power ω .

2

On the other side, we can use the following procedure to calculate the sample size required to
achieve specific power:

5 1. Calculate $var(X_1^*)$, $var(X_2^*)$ based on parameter settings.

6 2. Simulate samples to estimate ϕ_1 , ϕ_2 and \mathcal{T}_{true} .

7 3. Calculate n_1 using the sample size formula.

8

9 2.5. HANDLING MISSING UTILITY SCORES

10 In clinical studies, utility scores may not be available at each time point for all subjects, while the 11 current framework of HUS requires complete utility profiles to calculate the test statistic. The 12 most intuitive way is to impute the utility scores. We use linear functions to fill in the utility scores using the available data. If a subject's utility score is only available at one time point, then 13 we use that score as the imputed utility at all other time points. This approach may seem simple, 14 15 but it can be quite effective. Another method we consider is to impute the group average at each 16 key time point (i.e., each time point at which at least one subject has their utility score recorded), 17 and then use linear functions to fill in the other missing scores. This approach can be regarded as a combination of the cross-mean and linear interpolation methods³³. While imputing the group 18 19 average, we can also add some variation using a normal distribution with mean zero and its 20 standard deviation equal to the standard deviation of the recorded scores at that time point. In this way, the imputed values may be closer to the true values, which may lead to increase of 21 22 statistical power. It is also worth noting that many other methods are available for imputing 23 longitudinal data, and a very recent study has compared the effects of different imputation

methods and shown that most of them are similar in various scenarios, whereas trajectory mean
single imputation has the best overall performance³³. Hence, we consider trajectory mean
imputation as a third method. A comparison of the three methods using simulation results is
provided in the supplementary materials (Table S1), which shows that method 1 has much worse
performance when the missing rate is higher, while methods 2 and 3 are not affected as much.
For convenience, we use method 2 by default.

7 3. Results

8 3.1. SIMULATIONS WITH SIMPLIFIED SETTINGS

9 3.1.1 POWER COMPARISON

We conduct simulations in various scenarios to assess the performances of HUS. Suppose we are 10 11 designing a randomized clinical trial with two treatment arms. The total length of study is 36 months (T = 36), and each patient receives surgery at 3 months (C = 3). The two arms are 12 13 assigned to different treatment strategies to help them recover, and we are interested in 14 comparing the two treatments in terms of both survival and health utility. Denote the true survival time, observed survival time and survival status for patient *i* from group *g* as T_{gi} , X_{gi} 15 and δ_{ai} respectively. Group 1 and group 2 have sample sizes n_1 and n_2 . The survival data is 16 simulated using 17

$$T_{gi} \sim \operatorname{Exp}(h_g),$$

$$\xi_{gi} \sim \operatorname{Unif}(0, \zeta),$$

$$X_{gi} = \min(T_{gi}, \xi_{gi}, T),$$

$$\delta_{gi} = \begin{cases} 1 \ (T_{gi} < \xi_{gi} \text{ and } T_{gi} < T) \\ 0 \qquad (\text{otherwise})' \end{cases}$$

1 where ζ is chosen to control the censoring rate, denoted by $p_{\text{censoring}}$. The hazard ratio of

```
2 treatment 1 against treatment 2 is h_1/h_2.
```

3

4 To simulate the health utility score, we first define base utility functions for the two groups. The

5 base utility at time t for group g can be written as

$$U_{g0}(t) = \begin{cases} A_{g1} + \frac{A_{g2} - A_{g1}}{C}t & (0 \le t \le C) \\ \frac{TA_{g2} - CA_{g3}}{T - C} + \frac{A_{g3} - A_{g2}}{T - C}t & (C < t \le T) \end{cases}$$

This definition means the average utility for group g starts from A_{g1} at baseline, changes to A_{g2} at 3 months, and then changes to A_{g3} at the end of the study. The change is piecewise linear. Our motivation for this setting is that usually a cancer patient's health utility reaches the lowest at the end of treatment and gradually recovers after that. For patient *i* from group g, the health utility score at time *t*, denoted by $U_{gi}(t)$, follows a normal distribution with mean $U_{g0}(t)$ and standard deviation 0.1.

12

In practice, we do not expect health utility scores to be collected at each time point. Furthermore, some of the scores scheduled to be collected may be missing. For our main simulation study, we assume that the health utility scores are only collected at t = 1, C and T. When t = 1, all subjects have their utility scores collected. When t = C or T, the subjects that are still being followed have their utility scores collected, while there is a p_{missingU} chance that the score is missing.

1 In this section, we focus on the situation where the two treatment groups do not have a difference 2 in OS, which is the situation that motivated our HUS framework. Other situations (e.g., the two treatment groups differ in both OS and health utility) are explored in section 3.2 and the 3 4 supplementary materials (Tables S6-S9). Table 2 shows a summary of our major scenarios. In 5 each scenario, we compare the theoretical rejection rate using our results from section 2.4 and 6 the empirical rejection rates of HUS using bootstrap with B = 500. We consider three choices of λ_2 : $\lambda_2 = 1$ corresponds to the standard HUS approach; $\lambda_2 = 0.5$ means giving utility less weight 7 than survival; $\lambda_2 = 2$ means giving utility more weight than survival. We also examine the 8 9 performance of OS-based tests. In the tables, "sup" represents the log-rank test that tests whether group 1 is superior to group 2 in terms of OS using KM estimates. "5%" and "10%" correspond 10 11 to the inferiority test using the hazard ratio with margins 5% and 10% respectively. For instance, a 5% margin means we establish non-inferiority (treatment 1 is non-inferior to treatment 2 in 12 13 terms of OS) if the upper bound of the 95% CI of the hazard ratio is smaller than 1.05.

14

In scenario 0, we examine the rejection rates of different methods when the two treatment groups have the same OS and health utility. As shown in Table 3, all of the superiority tests are able to control type I errors at 0.05. The rejection rates of the non-inferiority tests are power instead of type I errors, since the alternative is true (treatment 1 is not inferior to treatment 2). This is why they may be higher than 0.05.

20

In scenario 1, we compare the power of different methods when treatment group 1 has better health utility than treatment group 2. For the theoretical power analysis, firstly, we run one simulation with $n_1 = n_2 = 200$ and 4000 replications to obtain the estimates $\phi_1 = 1.07$, $\phi_2 =$

1 1.12, $\mathcal{T}_{true} = 3.11$. Then we can calculate the power of different sample sizes. For the other 2 methods such as bootstrap $\lambda_2 = 1$, $\lambda_2 = 0.5$, and $\lambda_2 = 2$, we need to simulate new datasets (200 3 replications) with different sample sizes to get the empirical power. Note that ϕ_1 , ϕ_2 and \mathcal{T}_{true} 4 are quite robust to different sample sizes. For example, if we use $n_1 = n_2 = 500$, the obtained 5 estimates are $\phi_1 = 1.06$, $\phi_2 = 1.11$, $\mathcal{T}_{true} = 3.11$, which is very close to the scenario of $n_1 =$ 6 $n_2 = 200$. More results regarding the variance balance factors are provided in the supplementary 7 materials (Tables S2-S3).

8

As shown in Table 4, the bootstrap method with $\lambda_2 = 1$ performs close to the theoretical results, 9 which makes sense since the theoretical results are based on the standard HUS with $\lambda_2 = 1$. 10 Larger λ_2 tends to lead to higher power by giving more weight to utility than survival. This is 11 also expected because the two groups only differ in terms of utility. Meanwhile, the superiority 12 and non-inferiority tests based on OS have little power since there is no real difference in the two 13 group's OS. We also calculate the power corresponding to different sample sizes using our 14 theoretical results and plot the power curves in Figure 2. For scenario 1, to achieve 80% power, 15 using HUS as the endpoint only requires 85 subjects per arm. 16

17

In scenario 2, we increase the censoring rate to 60% and missing rates to 60%, and reduce the difference between the two group's health utility scores. As shown in Table 4 and Figure 2, results are very similar to those in scenario 1. Again, HUS is able to obtain decent power with relatively small sample sizes while the superiority and non-inferiority tests struggle to find enough evidence to show treatment 1's benefit compared to treatment 2. If we design a trial

based on HUS with the assumptions in scenario 2, we only need to have 151 patients in each
treatment group.

3

We would like to point out that even though choosing a larger λ₂ may seem to have higher
power in the above scenarios, it may not always be a good choice, especially when there is a
difference in OS. We recommend using λ₂ = 1 as default, though it can be modified depending
on the knowledge of the two treatments (e.g., whether treatment 1 is likely to have better OS than
treatment 2).

9

10 3.1.2 SAMPLE SIZE CALCULATION

11 In this subsection, we use our developed sample size calculation formulas to calculate sample 12 sizes needed for the composite endpoint, and the standard formulas to calculate sample sizes needed for basic survival endpoint (implemented in PASS 2023, v23.0.2 with the one-sided log-13 rank test), to further demonstrate the advantage of HUS. Following scenario 1 from 3.1.1, where 14 15 treatment 1 has better utility than treatment 2, we consider four different cases. In the first case, 16 there is no survival difference, which is consistent with the focus of this manuscript, and the 17 endpoint overall survival does not have power. In the second case, we assume that treatment 1 18 has better survival than treatment 2, while in the third case, we assume that treatment 2 has better 19 survival. In the last case, we assume treatment 1 has better survival, but there is no difference in 20 utility, and the utility function is the same as that in scenario 0. As shown in Table 5, with 21 scenario 1's utility functions, when h_1 is smaller than h_2 , meaning that treatment 1 has better OS 22 than treatment 2, the required sample size for HUS is decreased, which makes sense because the difference in HUS is larger. When h_1 is larger than h_2 , meaning that treatment 1 has worse OS 23

than treatment 2, the required sample size for HUS is increased. Nevertheless, the numbers are still much smaller than those calculated for overall survival. If there is no utility difference, HUS will require more subjects than overall survival, which is expected, though the difference is not as big. These results show again that using the composite endpoint may help greatly reduce the required sample size to detect a significant difference when two treatments differ in utility.

- 7 **Table 5.** Sample size calculation under a significance level of 0.05. When there is a utility
- 8 difference, utility functions from scenario 1 are used. When there is no utility difference, utility
- 9 functions from scenario 0 are used.

Utility: 1>2; survival: $1=2 (h_1/h_2 = 1)$						
Targeted power	Sample size require	Sample size requirement for each arm				
	HUS	OS				
70%	65	/				
80%	85	/				
90%	118	/				
Utility: 1>2; survival: 1>2 $(h_1/h_2 = 0.9)$						
Targeted power	Sample size requirement for each arm					
	HUS	OS				
70%	47	1710				
80%	62	2247				
90%	85	3112				
Util	ity: 1>2; survival: 1<2 $(h_1/h_2 =$	1.1)				
Targeted power	Sample size require	ement for each arm				
	HUS	OS				
70%	78	2243				
80%	103	2946				
90%	143	4080				

Utility: 1=2; survival: 1>2 $(h_1/h_2 = 0.7)$						
Targeted power	er Sample size requirement for each arm					
	HUS	OS				
70%	184	138				
80%	242	180				
90%	335	249				

1

2

3 3.3. SIMULATIONS WITH REAL DATA ESTIMATES

4 To demonstrate the benefit of HUS in a more practical scenario, we conduct additional 5 simulations with average utility scores and the hazard ratio mimicking the summary data provided in a real randomized trial PET-NECK.¹ PET-NECK is a randomized phase III non-6 7 inferiority trial that compares Positron emission tomography-computerized tomography-guided 8 watch-and-wait policy (PET-CT) with planned neck dissection (planned ND) for head and neck 9 cancer patients. The two-year overall survival rates of the two treatment groups (PET-CT and 10 planned ND) with 282 subjects per arm, are 84.9% and 81.5% respectively, which leads to a hazard ratio of 0.80. We conducted simulations utilizing the parameter setting to emulate the 11 12 survival times in PET-NECK. Figure 3 shows the average utility scores at different time points in the study, with the maximum time being 24 months. Hence, in this scenario, we set T = 24 and 13 14 define the base utility functions following the observed average utility scores. We also record the utilities at baseline and months 1, 3, 6, 12, 24 with 30% missing rate. Note that this scenario does 15 16 not fall into the framework of section 2.3, and thus we cannot apply our theoretical results 17 directly to calculate the power and sample sizes. However, obtaining the empirical results is similar to what we describe in section 3.1. 18

1

2	As shown in Table 6, with the two groups differing in both OS and health utility, the superiority
3	test based on HUS still has much higher power than the superiority and non-inferiority tests
4	based on OS. We would only need 200 subjects per arm to achieve 80% power of showing PET-
5	CT has better HUS than planned ND, which is fewer than the subjects in the original study which
6	were based on OS comparison. In terms of weighting, $\lambda_2 = 2$ again leads to higher power, while
7	$\lambda_2 = 0.5$ has lower power compared to the standard HUS. Nevertheless, in certain scenarios,
8	especially if the difference in health utility is small, using a larger λ_2 may not be as beneficial.
9	More results, including scenarios where there is no difference in health utility, are available in
10	the supplementary materials (Tables S6-S9, Figures S2-S4).
11	

12 4. DISCUSSION

13 We have presented a methodological framework to compare two treatment groups using HUS as 14 a composite endpoint combining survival and health utility. As demonstrated by our comprehensive simulation studies, when there is a difference in health utility, HUS has a 15 16 significant power advantage over the statistical tests based on OS endpoint, meaning that using HUS as an endpoint for new trials may require much smaller sample sizes to achieve decent 17 power. We have also demonstrated two different procedures (theoretical and empirical 18 19 approaches) to conduct power analysis and sample size calculation with specified parameters. 20 When the model assumptions are met, the two procedures yield similar results. There are several different options when applying HUS. We recommend using bootstrap given 21 22 its popularity as well as its convenience of constructing confidence intervals for the test statistic,

though permutation may be theoretically more appropriate for testing the null hypothesis, since it can obtain the null distribution of the test statistic. In terms of weighting on survival and utility, we recommend choosing weights $\lambda_1 = \lambda_2 = 1$ as default. Using a larger λ_2 may increase the power in certain scenarios, especially when the two treatment groups differ in health utility but not in OS. However, it may not be beneficial when there is no difference in health utility. A possible way to combine different weighting options without having to choose one is to apply an idea similar to the aSPU test.^{34, 35}

8

9 Note that the theoretical properties we have presented are based on assumptions by analogy with the assumptions used by Royston and Parmar,²⁹ though we have shown the validity of our 10 11 theoretical results in our simulations. In the future, we may explore the asymptotic properties 12 with relaxed assumptions (e.g., the survival times do not have to be piece-wise exponential), 13 which would be helpful when designing or analyzing trials where our previously used 14 assumptions are likely to be violated. We would also like to point out that the linear imputation method we use to fill in the utility scores may be problematic in some cases, especially if the 15 scores are only recorded at a few time points and the missing rate is high. We may consider other 16 17 imputation methods or modifying the definition of HUS so that it does not require complete utility score profiles as input.^{36, 37} Besides that, given the possible drawbacks brought by KM 18 19 estimates, sometimes it may be beneficial to apply other models, including the flexible parametric model for survival analysis.³⁸ 20

21

Another possible direction worth exploring is to take different functions of the utility score into
 consideration. One special case is that in many clinical studies, multiple measures of health

1 status are recorded. There are various ways to combine different measures into a single utility score.^{39–41} Extending HUS to be able to handle any function of utility may potentially increase 2 power and help us gain insight on how the utility is different in different treatment groups. 3 Furthermore, considering utility may have different importance at different time points, we may 4 5 assign different weights across time. For example, having a better utility score at the later stage of the study, which means the patients have recovered better, may be more important than having 6 7 a better utility score at the end of surgery. In such case, we can consider giving higher weights to 8 later time points, and the resulted HUS may provide a clearer picture of which treatment is more 9 beneficial for recovery.

10

11 5. DATA AVAILABILITY

12 R code for our simulation studies and summary data of health utility are available at

13 <u>https://github.com/yangq001/HUS</u>.

14

15 CONFLICTS OF INTEREST

16 The authors declare that there are no conflicts of interest.

17

18 ACKNOWLEDGMENTS

- 19 The authors would like to acknowledge the contributions of Dr. Hisham Mehanna (Institute of
- 20 Head and Neck Studies and Education, University of Birmingham) and Dr. Sue Yom
- 21 (Department of Radiation Oncology, University of California) for clinical insights and discussion.

1

2 FUNDING

- 3 This work was supported by the Alan Brown Chair in Molecular Genomics, the Lusi Wong Family Fund,
- 4 and the Posluns Family Fund, all through the Princess Margaret Cancer Foundation.

5

REFERENCES

1. Mehanna H, McConkey CC, Rahman JK, et al: PET-NECK: a multicentre randomised Phase III noninferiority trial comparing a positron emission tomography–computerised tomography-guided watch-andwait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technol Assess 21:1–122, 2017

2. Mathias SD, Bates MM, Pasta DJ, et al: Use of the Health Utilities Index With Stroke Patients and Their Caregivers. Stroke 28:1888–1894, 1997

3. Horsman J, Furlong W, Feeny D, et al: The Health Utilities Index (HUI®): concepts, measurement properties and applications. Health Qual Life Outcomes 1:54, 2003

4. Jewell EL, Smrtka M, Broadwater G, et al: Utility Scores and Treatment Preferences for Clinical Early-Stage Cervical Cancer. Value in Health 14:582–586, 2011

5. Glasziou PP, Simes RJ, Gelber RD: Quality adjusted survival analysis. Statist Med 9:1259–1276, 1990

6. Gelber RD: Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer. Ann Intern Med 114:621, 1991

 Gelber RD, Goldhirsch A, Cole BF, et al: A Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Adjuvant Radiation Therapy and Chemotherapy for Resectable Rectal Cancer.
 JNCI Journal of the National Cancer Institute 88:1039–1045, 1996

8. Murray S, Cole B: Variance and Sample Size Calculations in Quality-of-Life-Adjusted Survival Analysis (Q-TWiST). Biometrics 56:173–182, 2000

9. Konski AA, Winter K, Cole BF, et al: Quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) 90-03: Phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma. Head Neck 31:207–212, 2009

10. Zbrozek AS, Hudes G, Levy D, et al: Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma. Pharmacoeconomics 28:577–584, 2010

11. Seymour JF, Gaitonde P, Emeribe U, et al: A Quality-Adjusted Survival (Q-TWiST) Analysis to Assess Benefit-Risk of Acalabrutinib Versus Idelalisib/Bendamustine Plus Rituximab or Ibrutinib Among Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Patients. Blood 138:3722–3722, 2021

12. Jerusalem G, Delea TE, Martin M, et al: Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2– Advanced Breast Cancer in the MONALEESA-3 Trial. Clinical Breast Cancer 22:326–335, 2022

13. Glasziou PP, Cole BF, Gelber RD, et al: Quality adjusted survival analysis with repeated quality of life measures. Stat Med 17:1215–1229, 1998

14. Prieto L, Sacristán JA: Problems and solutions in calculating quality-adjusted life years (QALYs).Health Qual Life Outcomes 1:80, 2003

15. Whitehead SJ, Ali S: Health outcomes in economic evaluation: the QALY and utilities. British Medical Bulletin 96:5–21, 2010

16. Touray MML: Estimation of Quality-adjusted Life Years alongside clinical trials: the impact of 'timeeffects' on trial results. J Pharm Health Serv Res 9:109–114, 2018

17. Chung C-H, Hu T-H, Wang J-D, et al: Estimation of Quality-Adjusted Life Expectancy of Patients With Oral Cancer: Integration of Lifetime Survival With Repeated Quality-of-Life Measurements. Value in Health Regional Issues 21:59–65, 2020

 Laska EM, Meisner M, Siegel C: Power and Sample Size in Cost- Effectiveness Analysis. Med Decis Making 19:339–343, 1999

19. Willan AR, Lin DY: Incremental net benefit in randomized clinical trials. Statist Med 20:1563–1574,2001

20. Hollingworth W, McKell-Redwood D, Hampson L, et al: Cost–utility analysis conducted alongside randomized controlled trials: Are economic end points considered in sample size calculations and does it matter? Clinical Trials 10:43–53, 2013

21. Bader C, Cossin S, Maillard A, et al: A new approach for sample size calculation in cost-effectiveness studies based on value of information. BMC Med Res Methodol 18:113, 2018

22. Billingham LJ, Abrams KR, Jones DR: Methods for the analysis of quality-of-life and survival data in health technology assessment. Health Technol Assess 3:1–152, 1999

23. Diaby V, Adunlin G, Ali AA, et al: Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast Cancer Res Treat 146:669–673, 2014

24. Oza AM, Lorusso D, Aghajanian C, et al: Patient-Centered Outcomes in ARIEL3, a Phase III,
Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent
Ovarian Carcinoma. JCO 38:3494–3505, 2020

25. Good PI: Permutation, parametric and bootstrap tests of hypotheses 3rd ed. New York, Springer, 2005

26. Wu CFJ: Jackknife, Bootstrap and Other Resampling Methods in Regression Analysis [Internet]. Ann Statist 14, 1986[cited 2022 Dec 14] Available from: https://projecteuclid.org/journals/annals-ofstatistics/volume-14/issue-4/Jackknife-Bootstrap-and-Other-Resampling-Methods-in-Regression-Analysis/10.1214/aos/1176350142.full

27. Shao J, Tu D: The Jackknife and Bootstrap [Internet]. New York, NY, Springer New York, 1995[cited 2022 Dec 14] Available from: http://link.springer.com/10.1007/978-1-4612-0795-5

28. Myers ND, Ahn S, Jin Y: Sample Size and Power Estimates for a Confirmatory Factor Analytic Model in Exercise and Sport: A Monte Carlo Approach. Research Quarterly for Exercise and Sport 82:412–423, 2011

29. Royston P, Parmar MKB: Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol 13:152, 2013

30. Irwin JO: The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice. J Hyg 47:188–189, 1949

31. Royston P, Parmar MKB: The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Statist Med 30:2409–2421, 2011

32. Zhao L, Claggett B, Tian L, et al: On the restricted mean survival time curve in survival analysis: On the Restricted Mean Survival Time Curve in Survival Analysis. Biom 72:215–221, 2016

33. Jahangiri M, Kazemnejad A, Goldfeld KS, et al: A wide range of missing imputation approaches in longitudinal data: a simulation study and real data analysis. BMC Med Res Methodol 23:161, 2023

34. Pan W, Kim J, Zhang Y, et al: A Powerful and Adaptive Association Test for Rare Variants. Genetics 197:1081–1095, 2014

35. Kim J, Bai Y, Pan W: An Adaptive Association Test for Multiple Phenotypes with GWAS Summary Statistics. Genet Epidemiol 39:651–663, 2015

36. Naeim A, Keeler EB, Mangione CM: Options for Handling Missing Data in the Health Utilities Index Mark 3. Med Decis Making 25:186–198, 2005

37. Graham JW: Missing Data [Internet]. New York, NY, Springer New York, 2012[cited 2022 Dec 14] Available from: http://link.springer.com/10.1007/978-1-4614-4018-5

38. Lambert PC, Royston P: Further Development of Flexible Parametric Models for Survival Analysis. The Stata Journal 9:265–290, 2009

39. Hawthorne G, Richardson J, Day NA: A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments. Annals of Medicine 33:358–370, 2001

40. Fisk JD: A comparison of health utility measures for the evaluation of multiple sclerosis treatments. Journal of Neurology, Neurosurgery & Psychiatry 76:58–63, 2005

41. Pickard AS, Ray S, Ganguli A, et al: Comparison of FACT- and EQ-5D–Based Utility Scores in Cancer. Value in Health 15:305–311, 2012

Scenario	Non-Inferiority	Health Utility	Clinical Interpretation
	Interpretation	Interpretation	and Caveats
Survival non-inferior	New Treatment Non-	New Treatment	With composite
Improved Utility	Inferior	Superior	endpoint, patients and
			clinicians can be
			confident that weighted
			health utility adjusted
			survival is superior.
Survival non-inferior	New Treatment Non-	New Treatment Not	With non-inferiority
Worse Utility	Inferior	Superior	design, the new
			treatment may be
			falsely accepted as a
			treatment option
			despite worse utility
Survival non-inferior	New Treatment Non-	New Treatment Not	As above
Similar Utility	Inferior	Superior	
Survival Inferior	New Treatment Inferior	New Treatment may be	With non-inferiority
Improved Utility		Superior, Similar or	design new option is
		Worse Depending on	rejected as non-inferior.
		magnitude of effect	However, if there is a
			large therapeutic
			benefit with the new
			intervention a
			composite endpoint

Table 1. Interpretations for different scenarios of survival and utility.

			may demonstrated this
			new treatment to be
			superior.
Survival Inferior	New Treatment Inferior	New Treatment Inferior	Non-Inferior design
Worse Utility			may appropriately
			declare new treatment
			as inferior
Survival Inferior	New Treatment Inferior	New Treatment Inferior	As above
Similar Utility			

Table 2. Simulation settings with different scenario.

Scenario	$p_{ m censoring}$	$p_{ m missingU}$	Average utility			
			Group	Baseline	3 months	36 months
0	30%	30%	1	0.8	0.4	0.7
			2	0.8	0.4	0.7
1	30%	30%	1	0.8	0.5	0.8
			2	0.8	0.35	0.7
2	60%	60%	1	0.8	0.5	0.8
			2	0.8	0.4	0.7

Table 3. Rejection rates of different methods in scenario 0 based on 1000 replications.

<i>n</i> ₁ , <i>n</i> ₂		HU	JS	OS			
	Theoretical	Bootstrap	$\lambda_2 = 0.5$	$\lambda_2 = 2$	Superiority	Non-	Non-
		$(\lambda_2 = 1)$			test	inferiority	inferiority
						test with	test with
						margin	margin
						5%	10%
50	0.052	0.052	0.050	0.053	0.056	0.040	0.050
100	0.052	0.054	0.053	0.051	0.068	0.051	0.073
150	0.053	0.047	0.052	0.048	0.054	0.042	0.079
200	0.053	0.052	0.046	0.048	0.053	0.050	0.092
500	0.054	0.049	0.051	0.050	0.045	0.083	0.184

Table 4. Power comparison of different methods in scenarios 1 and 2 based on 200 replications.

Scenario 1								
<i>n</i> ₁ , <i>n</i> ₂		Н	JS			OS		
	Theoretical	Bootstrap	$\lambda_2 = 0.5$	$\lambda_2 = 2$	Superiority	Non-	Non-	
		$(\lambda_2 = 1)$			test	inferiority	inferiority	
						test with	test with	
						margin	margin	
						5%	10%	

50	0.61	0.56	0.28	0.9	0.05	0.04	0.05
100	0.86	0.85	0.44	1	0.05	0.05	0.07
150	0.95	0.95	0.59	1	0.05	0.06	0.1
200	0.99	1	0.71	1	0.06	0.04	0.06
			Scen	ario 2			
n ₁ , n ₂	2 HUS OS						
	Theoretical	Bootstrap	$\lambda_2 = 0.5$	$\lambda_2 = 2$	Superiority	Non-	Non-
		$(\lambda_2 = 1)$			test	inferiority	inferiority
						test with	test with
						margin	margin
						5%	10%
50	0.42	0.42	0.2	0.76	0.05	0.04	0.06
100	0.65	0.67	0.31	0.94	0.06	0.06	0.08
150	0.80	0.82	0.42	0.97	0.06	0.05	0.1
200	0.89	0.92	0.48	1	0.05	0.05	0.06

Table 6. Power comparison for simulations using real data estimates.

n_1, n_2	HUS	OS

	Bootstrap	$\lambda_2 = 0.5$	$\lambda_2 = 2$	Superiority	Non-	Non-
	$(\lambda_2 = 1)$			test	inferiority	inferiority
					test with	test with
					margin 5%	margin 10%
50	0.34	0.26	0.47	0.09	0.1	0.12
100						
100	0.54	0.4	0.69	0.14	0.17	0.22
150	0.74	0.54	0.84	0.19	0.24	0.34
200	0.82	0.61	0.97	0.2	0.25	0.33
282	0.94	0.76	0.99	0.27	0.36	0.44





